Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

EADV: Imiquimod May Eradicate Superficial Basal Cell Carcinoma By Bonnie Darves BARCELONA, SPAIN -- October 24, 2003 -- Six weeks of treatment with imiquimod 5% cream may help eradicate superficial basal cell carcinoma, based on results of a new European study presented here at the European Academy of Dermatology & Venereology Congress. As the efficacy and safety results of this open-label Phase III study were more promising than expected, imiquimod 5% (IQ-5) may emerge as a noninvasive treatment for early-stage basal cell cancers, said lead investigator Harald Gollnick, MD, University of Dermatology and Venereology, Magdeburg, Germany, provided continued follow-up studies -- including this continuing study -- confirm that recurrence rates remain low. The multicentre study, involving 182 European Caucasian patients (predominantly male and with a mean age of 65 years), evaluated the long-term safety and efficacy of IQ-5 in eradicating tumours with a minimum area of 0.5 cm2 and a maximum diameter of 2.0 cm. Median tumour size was 1.0 cm, and the majority of sites treated were on the trunk. Initial clearance rate was 90%. Nearly 90% of subjects reported that they have tanned "minimally" in the past. Patients were treated with IQ-5 cream 5 days a week for 6 weeks, and were assessed at 6 months, 12 months and annually. Assessment will continue for a total period of 4 years. Based on the first year's results, IQ-5 was both safe and efficacious, with minimal adverse events. Approximately 92% of subjects had achieved clearance at 12 weeks post-treatment, and of those subjects, 97.4% retained a sustained clearance rate of 97% by Month 12. Adverse events, primarily application site reactions, affected 19% of patients. But most were mild and resolved after treatment was discontinued. To date, three subjects in the 25-centre study have discontinued because of adverse events, Dr. Gollnick noted, confirming that IQ-5 is a safe alternative treatment starting point for non-advanced basal cell tumours. [Study title: Long-term Efficacy of Imiquimod 5% Cream for Treatment of Superficial Basal Cell Carcinoma: a European Study. Poster 5-17] E-mail this page to a friend or colleague! To print, use this version